Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Background: Hilar cholangiocarcinoma (hCCA) is an aggressive malignancy with limited therapeutic options and poor prognosis, particularly in patients with unresectable or metastatic disease. Although immune checkpoint inhibitors and targeted therapies have improved outcomes, resistance remains a major challenge. Here, we report a case of metastatic hCCA with possible lenvatinib resistance managed by sequential molecular-guided therapy.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.